Our pipeline

With an unmatched understanding of the mechanisms of hearing disorders in neurodegeneration and inflammation, CILcare has developed a proprietary pipeline of compounds. CILcare’s excellence led to the selection of a derisked & robust pipeline.

CILcare’s assets are currently in preclinical phases. The main goal is to develop targeted therapies to treat the early signs of age-related hearing disorders and to delay the onset of neurodegenerative and inflammatory diseases.

CILcare pipeline

CILcare’s ambition is to continue partnering with life sciences companies looking for external innovations in the field of ear disorders and related conditions.

Learn more about CILcare’s expertise here.

Follow CILcare’s news on LinkedIn.